Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Cancer Discov. 2020 Oct 18;10(12):1826–1841. doi: 10.1158/2159-8290.CD-20-0282

Figure 1: KEAP1/NFE2L2 mutations are predictive biomarkers of local recurrence after radiotherapy.

Figure 1:

(A) Study design (images were produced and modified from Servier Medical Art, see Acknowledgements). (B) Recurrent mutations in patients with and without local recurrence (LR) after chemoradiotherapy (CRT) or stereotactic ablative radiotherapy (SABR). (C) Association of recurrent mutations with LR. Competing risk comparison performed using Gray’s test with multiple hypothesis testing correction. (D) Pie chart fraction of LR events occurring in tumors with KEAP1 or NFE2L2 mutations. (E) Location of KEAP1 and NFE2L2 mutations from CRT and SABR cohorts. (F) Incidence of local recurrence stratified by KEAP1/NFE2L2 mutation status for patients with stage IIB-IIIC NSCLC receiving CRT. (G) Incidence of LR stratified by KEAP1/NFE2L2 mutation status for patients with stage IA1-IIB NSCLC treated with SABR. (H) Incidence of LR stratified by KEAP1/NFE2L2 mutation status for patients with stage IA1-IIB NSCLC treated with surgical resection.